Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Atorvastatin

Drug Profile

Atorvastatin

Alternative Names: Atorvastatin calcium; Cardyl; CI 981; Lipitor; Prevencor; Sortis; Tahor; Xarator 10; YM 548; Zarator

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Pfizer
  • Developer Astellas Pharma; Laboratorios Phoenix; Pfizer; University of Rochester
  • Class Amides; Antihyperlipidaemics; Fatty acids; Fluorobenzenes; Heptanoic acids; Pyrroles; Small molecules
  • Mechanism of Action HMG-CoA reductase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Cardiovascular disorders; Heart failure; Hypercholesterolaemia; Hyperlipoproteinaemia type IIa; Hyperlipoproteinaemia type III; Hypertriglyceridaemia; Low HDL cholesterol
  • Phase III Veno-occlusive disorders
  • Phase I/II Metabolic syndrome
  • Discontinued Alzheimer's disease; Neurological disorders

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 01 Jan 2017 Pfizer and Boca Raton Regional Hospital completes a phase III trial in Veno-occlusive disorders in USA and Canada (NCT01528709)
  • 09 Oct 2015 No recent reports on development identified - Phase-II/III for Hyperlipoproteinaemia type IIa (In adolescents, In children) in Switzerland (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top